Prognostic impact of CD20 expression in adult B-cell acute lymphoblastic leukemia
Expression of CD20 in adult B-cell acute lymphoblastic leukemia has been associated with a poor prognosis. Previous studies suggest treatment with rituximab can significantly improve event-free, though not overall survival. Results from this study in Hispanic ALL-B patients support the role of CD20 as a determinant of poor prognosis, and suggest that treatment with rituximab offers a significant benefit. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 26, 2018 Category: Hematology Authors: Reib án-Espinoza Esteban, Bourlon Christianne, Aguayo Alvaro, Demichelis-Gómez Roberta Tags: Original Study Source Type: research

Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
The complete molecular response (CMR) and overall survival (OS) in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia treated with front-line chemotherapy plus ponatinib versus earlier generation tyrosine kinase inhibitors were compared in a meta-analysis and meta-regression. The patients treated with front-line ponatinib versus earlier generation treatments were more likely to achieve a CMR and had greater rates of 3-year OS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 17, 2018 Category: Hematology Authors: Elias Jabbour, Maral DerSarkissian, Mei Sheng Duh, Nora McCormick, Wendy Y. Cheng, Lisa J. McGarry, Ariadne Souroutzidis, Hui Huang, Susan O ’Brien, Farhad Ravandi, Hagop M. Kantarjian Tags: Original Study Source Type: research

Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report
Prognostic factors of second allogeneic stem-cell transplantation (allo-SCT2) in 78 patients with relapsed acute myeloid leukemia after first transplantation were explored. Factors included poor cytogenetic risk at diagnosis, circulating blast  ≥ 20% at relapse, duration from first transplantation to relapse of  (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 17, 2018 Category: Hematology Authors: Sung-Soo Park, Hee-Je Kim, Kyoung Il Min, Gi June Min, Young-Woo Jeon, Jae-Ho Yoon, Seung-Ah Yahng, Seung-Hwan Shin, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Woo-Sung Min Tags: Original Study Source Type: research

Risk Factors Influencing Outcome of Acute Leukemia Patients Who Experience Relapse After Allogeneic Hematopoietic Stem-Cell Transplantation
In a study of 43 patients to assess the risk factors influencing relapse outcome after hematopoietic stem-cell transplantation in acute leukemia, older age and failure to experience complete remission (CR) after treatment were associated with inferior overall survival. Female sex, extramedullary relapse, and absence of postrelapse graft-versus-host disease (GVHD) were associated with lower CR; and absence of extramedullary relapse, treatment with donor lymphocyte infusion, and occurrence of postrelapse GVHD were associated with higher nonrelapse mortality. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 17, 2018 Category: Hematology Authors: Amro M.S. El-Ghammaz, Mostafa K. El-Razzaz Tags: Original Study Source Type: research

Risk factors influencing outcome of acute leukemia patients relapsing after allogeneic hematopoietic stem cell transplantation
Identifying risk factors influencing post-HSCT relapse outcome in acute leukemia is essential. 43 patients were studied. Older age and failure to achieve CR following treatment were associated with inferior OS. Female sex, extramedullary relapse and absence of post-relapse GVHD were associated with lower CR. Absence of extramedullary relapse, treatment with DLI and occurrence of post-relapse GVHD were associated with higher NRM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 17, 2018 Category: Hematology Authors: Amro M.S. El-Ghammaz, Mostafa K. El-Razzaz Tags: Original Study Source Type: research

Prognostic Biomarkers in the Progression from MGUS to Multiple Myeloma: a Systematic Review
Multiple myeloma (MM), characterized by malignant plasma cells in the bone marrow (BM), is consistently preceded by asymptomatic pre-malignant stage monoclonal gammopathy of undetermined significance (MGUS). These MGUS patients have an annual risk of 1% to progress to MM. Clinical, imaging and genomic (genetic and epigenetic) factors were identified, whose presence increased the risk of progression from MGUS to MM. This systematic review summarizes the currently identified clinical, imaging and genomic biomarkers, suggested to increase the progression risk or demonstrated to be differential expressed/presence between both ...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 17, 2018 Category: Hematology Authors: Cosemans Charlotte, Oben B énedith, Arijs Ingrid, Daniëls Annick, Declercq Jeroen, Vanhees Kimberly, Froyen Guy, Maes Brigitte, Mebis Jeroen, Rummens Jean-Luc Tags: Review Article Source Type: research

Efficacy of Ponatinib versus Earlier-Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
Complete molecular response (CMR) and overall survival (OS) in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) treated with front-line chemotherapy plus ponatinib versus earlier-generation tyrosine kinase inhibitors (TKIs) were compared in a meta-analysis and meta-regression. Patients treated with front-line ponatinib versus earlier-generation treatments were more likely to achieve CMR and had higher rates of 3-year OS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 17, 2018 Category: Hematology Authors: Elias Jabbour, Maral DerSarkissian, Mei Sheng Duh, Nora McCormick, Wendy Y. Cheng, Lisa J. McGarry, Ariadne Souroutzidis, Hui Huang, Susan O ’Brien, Farhad Ravandi, Hagop M. Kantarjian Tags: Original Study Source Type: research

A prognostic prediction model for second allogeneic stem cell transplantation in patients with relapsed acute myeloid leukemia: single center report
Prognostic factors of second allogeneic stem cell transplantation (allo-SCT2) in 78 patients with relapsed AML after first transplantation were explored. Those were poor cytogenetic risk at diagnosis, circulating blast ≥ 20% at relapse, duration from first transplant to relapse (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 17, 2018 Category: Hematology Authors: Sung-Soo Park, Hee-Je Kim, Kyoung Il Min, Gi June Min, Young-Woo Jeon, Jae-Ho Yoon, Seung-Ah Yahng, Seung-Hwan Shin, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Woo-Sung Min Tags: Original Study Source Type: research

Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma
High-dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed lymphoma. We retrospectively analyzed the data from 212 lymphoma patients who had undergone ASCT with the TECAM conditioning regimen. The 3-year overall survival, progression-free survival, and death resulting from treatment were comparable to those reported with other conditioning regimens. Our results justify evaluation of TECAM in a prospective multicenter study (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2018 Category: Hematology Authors: Sigal Grisariu, Michael Y. Shapira, Reuven Or, Batia Avni Tags: Original Study Source Type: research

A Retrospective Study of Double-hit Lymphomas  in Elderly Patients (Aged  >  70 Years): Overall Outcomes
Double-hit lymphoma can be an aggressive disease that is difficult to treat in the elderly population. We evaluated patients aged> 70 years and their outcomes after treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), R-EPOCH (rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin), and other chemotherapy regimens. The results showed the outcomes were dependent on patient performance status and comorbidities. Intensive regimens should be considered for elderly patients who are medically fit. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2018 Category: Hematology Authors: Christie Hancock, Phillip Knouse, Imad Almanaseer, Jacob Bitran Tags: Original Study Source Type: research

Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A  Thirty-year Experience
Primary cutaneous lymphomas are a heterogeneous group of extranodal non-Hodgkin lymphomas, approximately 25% of which are B-cell derived, which have are classified into 3 major entities since 2005: primary cutaneous follicle-center lymphoma (PCFCL), primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), and primary cutaneous marginal zone lymphoma (PCMZL).1,2 In 2016, a very rare entity, intravascular lymphoma, was introduced and predominantly involves the skin.3 The diagnosis and classification of primary cutaneous B-cell lymphoma (PCBCL) requires an excisional or punch biopsy for careful morphologic and ...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2018 Category: Hematology Authors: Vittorio Stefoni, Alessandro Broccoli, Lisa Argnani, Elena Sabattini, Michele Cavo, Pier Luigi Zinzani Tags: Case Report Source Type: research

Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: a Thirty-year Experience
Primary cutaneous lymphomas are a heterogeneous group of extranodal non-Hodgkin lymphomas, approximately 25% of which are B-cell derived and are classified into three major entities in the since 2005 World Health Organization (WHO)-European Organization for Research and Treatment of Cancer (EORTC) joint classification: primary cutaneous follicle-center lymphoma (PCFCL), primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), and primary cutaneous marginal zone lymphoma (PCMZL).1,2 In 2016, a very rare entity, the intravascular, was introduced as predominantly involves skin. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2018 Category: Hematology Authors: Vittorio Stefoni, Alessandro Broccoli, Lisa Argnani, Elena Sabattini, Michele Cavo, Pier Luigi Zinzani Tags: Case Report Source Type: research

Thiotepa, Etoposide, Cyclophosphamide, ARA-C and Melphalan (TECAM) conditioning regimen for autologous stem cell transplantation in lymphoma
High dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). Conditioning regimens with high dose BCNU are associated with Idiopathic Pneumonitis Syndrome (IPS). We therefore created a modified alternative TECAM conditioning regimen, consisting of etoposide, thiotepa, cytarabine, cyclophosphamide and melphalan. We retrospectively analyzed our cohort of NHL and HL patients, who underwent ASCT with the TECAM conditioning between 2000 and 2013. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2018 Category: Hematology Authors: Sigal Grisariu, Michael Y. Shapira, Reuven Or, Batia Avni Tags: Original Study Source Type: research

A Retrospective Study of Double-Hit Lymphomas in Elderly Patients ( > 70 years): Overall Outcomes
There is an increasing frequency of double-hit diffuse large B-cell lymphomas, which represent at least 4% of all diffuse large B-cell lymphoma (DLBCL).1 These double-hit lymphomas (DHLs) have been defined by the 2016 WHO classification as high-grade diffuse large B cell lymphomas with translocations involving c-myc in combination with translocations of bcl-2 and/or bcl-6.2 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2018 Category: Hematology Authors: Christie Hancock, Phillip Knouse, Imad Almanaseer, Jacob Bitran Tags: Original Study Source Type: research

Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
Whithin the EURO-SKI trial, 132 chronic phase CML patients discontinued imatinib treatment. RNA was isolated from peripheral blood in order to analyze the expression of MDR1, ABCG2 and OCT1. ABCG2 was predictive for treatment-free remission in Cox regression analysis. High transcript levels of the ABCG2 efflux transporter (>4.5 ‰) were associated with a twofold higher risk of relapse. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 7, 2018 Category: Hematology Authors: S ébastien Rinaldetti, Markus Pfirrmann, Kirsi Manz, Joelle Guilhot, Christian Dietz, Panayiotidis Panagiotidis, Birgit Spiess, Wolfgang Seifarth, Alice Fabarius, Martin Müller, Maria Pagoni, Maria Dimou, Jolanta Dengler, Cornelius F. Waller, Tim H. Br Tags: Original Study Source Type: research

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). However, this treatment regimen is not appropriate for elderly and/or comorbid patients; in these cases, azacitidine is a standard treatment. This systematic review was conducted to evaluate real-world evidence of treatment options for patients with HR-MDS/CMML. Medline and Embase (January 2006 to May 2016) were searched, in addition to conference proceedings and treatment guideline reviews. (Sou...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 7, 2018 Category: Hematology Authors: Jill A. Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. Faller Tags: Review Source Type: research

Azacitidine use for myeloid neoplasms
Azacitidine and decitabine are hypomethylating agents frequently used interchangeably to treat myeloid neoplasms in different settings. Azacitidine is metabolized intracellularly into decitabine. Hypomethylating agents work by inhibiting DNA methyltransferases, causing demethylation of aberrantly methylated promoter regions of genes involved in the pathogenesis of myeloid neoplasms. Azacitidine was the first agent approved for treatment of MDS in 2004. After FDA approval, the use of azacitidine in other myeloid neoplasms increased significantly. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 7, 2018 Category: Hematology Authors: Riad El Fakih, Mona Hassanein, Marwan Shaheen, Walid Rasheed, Fahad Almohareb, Rami Komrokji Tags: Review Article Source Type: research

Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, with a Focus on Elderly CLL Patients
Chronic lymphocytic leukemia (CLL) remains the most prevalent form of leukemia in the western world, with no cure to date. Ongoing and essential research into this heterogeneous disease has led to a number of new treatment options becoming available to CLL patients in the last decade. This review looks at the recent developments in the field of CLL treatment, with the main focus on elderly patients and CLL patients with co-existing comorbidities. The review discusses the current treatment regimens which provide the most promising outcomes for patients of this subgroup, with a number of important clinical trials summarized....
Source: Clinical Lymphoma, Myeloma and Leukemia - February 7, 2018 Category: Hematology Authors: Alma O. Reillya, James Murphya, Sarah Raweb, Mary Garveya Tags: Review Article Source Type: research

Systematic literature review of treatment options and clinical outcomes for patients with higher risk myelodysplastic syndromes and chronic myelomonocytic leukemia
High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). However, this treatment regimen is not appropriate for elderly and/or comorbid patients; in these cases, azacitidine is a standard treatment. This systematic review was conducted to evaluate real-world evidence of treatment options for patients with HR-MDS/CMML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 7, 2018 Category: Hematology Authors: Jill A. Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. Faller Tags: Review Article Source Type: research

Outcomes of adolescents and young adults with acute myeloid leukemia treated in a single Latin American Center
Hispanic patients younger than 40 years diagnosed with acute myeloid leukemia (AML) during 2003-2016 in Northeast Mexico were evaluated. The group included 46 children and 88 adolescents and young adults (AYA) from 15-39 years. A higher overall response rate was found in children, 87.2% vs. 69% in AYA. Low EFS and OS rates for AML patients in AYA were documented. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 7, 2018 Category: Hematology Authors: Jos é Carlos Jaime-Pérez, José Ramón Padilla-Medina, Lucía Teresa Fernández, José Luis Herrera-Garza, César Homero Gutiérrez-Aguirre, Luz Tarín-Arzaga, David Gómez-Almaguer Tags: Original Study Source Type: research

Impact of Abcg2, Oct1 And Abcb1 (Mdr1) Gene Expression on Treatment-Free Remission In A Euro-Ski Subtrial
Tyrosine kinase inhibitors (TKIs) can safely be discontinued in chronic myeloid leukemia (CML) patients with sustained deep molecular response (DMR). ABCG2, OCT1 and ABCB1 (MDR1) gene products are known to play a crucial role in acquired pharmacogenetic TKI resistance. Their influence on treatment-free remission (TFR) has not yet been investigated. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 7, 2018 Category: Hematology Authors: S ébastien Rinaldetti, Markus Pfirmann, Kirsi Manz, Joelle Guilhot, Christian Dietz, Panayiotidis Panagiotidis, Birgit Spiess, Wolfgang Seifarth, Alice Fabarius, Martin Müller, Maria Pagoni, Maria Dimou, Jolanta Dengler, Cornelius Waller, Tim H. Brümme Tags: Original Study Source Type: research

Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma
It is unclear how medication adherence affects the burden of multiple myeloma (MM). Overall, 162 adults with MM completed an online survey. Better medication adherence related to less impairment to work productivity and functioning, lower out of pocket costs, and fewer office visits. With increased survival, considering the quality of life for patients with MM will be essential. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2018 Category: Hematology Authors: Shaloo Gupta, Safiya Abouzaid, Ryan Liebert, Kejal Parikh, Brian Ung, Aaron S. Rosenberg Tags: Original Study Source Type: research

Assessing the Effect of Adherence on Patient Reported Outcomes and Out of Pocket Costs among Patients with Multiple Myeloma
It is unclear how medication adherence impacts the burden of multiple myeloma (MM). Overall, 162 adults with MM completed an online survey. Better medication adherence related to less impairment to work productivity and functioning, lower out of pocket costs, and fewer office visits. With increased survival, considering quality of life for patients with MM will be essential. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2018 Category: Hematology Authors: Shaloo Gupta, Safiya Abouzaid, Ryan Liebert, Kejal Parikh, Brian Ung, Aaron S. Rosenberg Source Type: research

Undertreatment of Older Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
With the expanding armamentarium of therapeutic agents in multiple myeloma (MM), it is important to identify any undertreated patient populations to mitigate outcome disparities. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2018 Category: Hematology Authors: Bita Fakhri, Mark A. Fiala, Sascha A. Tuchman, Tanya M. Wildes Tags: Original Study Source Type: research

Outcome of chronic myeloid leukemia-chronic phase patients treated with imatinib: A local experience
In this study, we assessed the efficacy and toxicity of imatinib therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) in our hospital. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2018 Category: Hematology Authors: Ali M. Al-Amri Tags: Original Study Source Type: research

Marrow Hypocellularity, but Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients with Morphologic Residual Disease
Induction chemotherapy for acute myeloid leukemia (AML) is based on the “7+3” cytarabine/anthracycline regimen. A non hypocellular day 14 (D14) marrow with a blast count greater than 5-10% is suggestive of residual leukemia for which a second course of induction chemotherapy is recommended. Although the prognostic value of D14 marrow has been established, its use as a decision point is controversial as the benefit of repeat induction is questionable. In this single-center retrospective study of 113 patients with newly diagnosed AML, we evaluated the role of cellularity on clinical outcomes in patients with resi...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2018 Category: Hematology Authors: Thomas A. Ollila, Adam J. Olszewski, James N. Butera, Matthew I. Quesenberry, Peter J. Quesenberry, John L. Reagan Tags: Original Study Source Type: research

Safety and Preliminary Efficacy of Vorinostat With  R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)
We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacious with chemotherapy with complete response rate of 83% and 1-year event-free survival of 83%. VOR did not significantly alter chemotherapy steady-state concentrations, CD4+ cell counts, or HIV viral loads. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 2, 2018 Category: Hematology Authors: Juan C. Ramos, Joseph A. Sparano, Michelle A. Rudek, Page C. Moore, Ethel Cesarman, Erin G. Reid, David Henry, Lee Ratner, David Aboulafia, Jeanette Y. Lee, Richard F. Ambinder, Ronald Mitsuyasu, Ariela Noy Tags: Original Study Source Type: research

Safety and Preliminary Efficacy of Vorinostat with R-EPOCH in High-risk HIV-associated Non-Hodgkin ’s Lymphoma (AMC-075)
Vorinostat (VOR), a histone deacetylase inhibitor, enhances the anti-tumor effects of rituximab (R) and cytotoxic chemotherapy, induces viral lytic expression and cell killing in EBV+ or HHV-8+ tumors, and reactivates latent human immunodeficiency virus (HIV) for possible eradication by combination antiretroviral therapy (cART). We performed a phase I trial of VOR given with R-based infusional EPOCH (n=12) and cART in aggressive HIV-associated B-cell non-Hodgkin lymphoma (NHL) in order to identify safe dosing and schedule. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 2, 2018 Category: Hematology Authors: Juan C. Ramos, Joseph A. Sparano, Michelle A. Rudek, Page C. Moore, Ethel Cesarman, Erin G. Reid, David Henry, Lee Ratner, David Aboulafia, Jeanette Y. Lee, Richard F. Ambinder, Ronald Mitsuyasu, Ariela Noy Tags: Original Study Source Type: research

Abnormal heavy/light chain ratio and matched pair suppression increase residual disease detection sensitivity in patients with multiple myeloma with deep responses
Heavy/light chain (HLC) assay can quantify both involved and uninvolved immunoglobulin pairs and is used to detect monoclonal proteins. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 2, 2018 Category: Hematology Authors: Kanji Miyazaki, Kenshi Suzuki Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 1, 2018 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 1, 2018 Category: Hematology Source Type: research

Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial
Hodgkin lymphoma is a curable disease with outcomes depending on initial prognostic factors and interim treatment response. Here, we conducted a phase II trial in advanced stage Hodgkin lymphoma to assess the feasibility and efficacy of a positron emission tomography-adapted strategy with early salvage for poor metabolic responders. We show that this strategy is feasible and leads to interesting results for the whole population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 21, 2018 Category: Hematology Authors: Sylvain Carras, Benjamin Dubois, Delphine Senecal, Jean-Philippe Jais, Michel Peoc'h, Philippe Quittet, Charles Foussard, Krimo Bouabdallah, Thomas Gastinne, Eric Jourdan, Laurence Sanhes, Marjan Ertault, Thierry Lamy, Lysiane Molina Tags: Original Study Source Type: research

Interim PET response adapted strategy in untreated advanced stage Hodgkin Lymphoma : results of GOELAMS LH 2007 phase 2 multicentric trial
Patients with advanced stage Hodgkin Lymphomas still present unsatisfactory outcomes. The GOELAMS group conducted a prospective multicentric trial (NCT00920153) for advanced stage HL to evaluate a PET adapted strategy. Patients received an intensive regimen (VABEM) in front-line and interim 18FFDG-PET evaluation after 2 courses (PET-2). Negative PET-2 patients received one additional course. Positive PET-2 patients underwent early salvage therapy followed by HDT/ASCT. Fifty-one patients were included. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 21, 2018 Category: Hematology Authors: S. Carras, B. Dubois, D. Senecal, J.P. Jais, M. Peoc ’h, P. Quittet, C. Foussard, K. Bouabdallah, T. Gastinne, Eric Jourdan, L. Sanhes, M. Ertault, T. Lamy, L. Molina Tags: Original Study Source Type: research

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation
This retrospective study analyzed the long-term outcome of 75 patients with t(4;14) multiple myeloma treated in a single center with frontline bortezomib-based treatment. Frontline autologous stem cell transplant following bortezomib-based induction was associated with better progression-free survival. These results further support the use of frontline autologous stem cell transplant, especially among patients with high-risk cytogenetics. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Henry Chan, Madeline Phillips, Manjula Maganti, Sophia Farooki, Giovanni Piza Rodriguez, Esther Masih-Khan, Christine Chen, Anca Prica, Donna Reece, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti Tags: Original Study Source Type: research

Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction
This study analyzed the efficacy of pegfilgrastim in stem cell (PBSC) mobilization compared to filgrastim, exclusively after NA-based induction in a homogeneous group of MM patients. We analyzed 89 patients with MM treated at 2 transplant centers in Singapore who received NA-based induction chemotherapy, PBSC mobilization with vinorelbine/cyclophosphamide, high-dose melphalan conditioning and ASCT. This study demonstrates that a single dose of pegfilgrastim is comparable to filgrastim in terms of the timing and efficacy of PBSC harvest and could potentially spare the patient of 6 days of filgrastim injections. (Source: Cli...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Muhammad Bilal Abid, Sanjay De Mel, Muhammad Abbas Abid, Eng Soo Yap, Sathish Kumar Gopalakrishnan, Yunxin Chen, Yi Ching Yuen, Hung Chew Wong, Adeline Lin, Li Mei Poon, Liang Piu Koh, Wee Joo Chng, Lip Kun Tan Tags: Original Study Source Type: research

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States
Despite the emerging paradigm favoring continuous therapy, we report that in routine clinical care, myeloma patients at first relapse frequently discontinue treatment before progression, resulting in duration of therapy that is significantly shorter than time to next therapy. We further describe the association between length of therapy in second line and improved overall survival in patients with relapsed/refractory multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Parameswaran Hari, Dorothy Romanus, Antonio Palumbo, Katarina Luptakova, Robert M. Rifkin, Linh Mai Tran, Aditya Raju, Eileen Farrelly, Stephen J. Noga, Marlo Blazer, Ajai Chari Tags: Original Study Source Type: research

Pegylated Filgrastim vs. Filgrastim for Stem Cell Mobilization in Multiple Myeloma after Novel Agent Induction
The current standard of care for transplant-eligible myeloma patients is novel agent-based induction followed by high-dose chemotherapy and autologous stem cell rescue. Chemo-mobilization of peripheral blood CD34+ stem cells (PBSC) with pegylated filgrastim (pegfilgrastim), a sustained-duration formulation of filgrastim, has been used as an alternative to filgrastim in several studies involving heterogeneous cohorts of lymphoma and multiple myeloma (MM) patients and shown to be equivalent in PBSC yield and cost-effectiveness. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Muhammad Bilal Abid, SanjayDe Mel, Muhammad Abbas Abid, Eng Soo Yap, Sathish Kumar Gopalakrishnan, Yunxin Chen, Yi Ching Yuen, Hung Chew Wong, Adeline Lin, Michelle Poon Limei, Liang Piu Koh, Wee Joo Chng, Lip Kun Tan Tags: Original Study Source Type: research

Single center experience in treating patients with t(4;14) multiple myeloma with and without planned frontline autologous stem cell transplantation
Multiple myeloma (MM) is a malignant plasma cell condition with variable long-term outcomes. Depending on the patients ’ risk factors, long-term overall survival can range from under 2 years to more than 10 years [1, 2]. One of the most important prognostic factors in this condition is disease cytogenetics, which are now commonly assessed using fluorescent in-situ hybridization (FISH) [1-3]. Amongst all of the cyt ogenetic abnormalities detected by FISH that are deemed as high-risk, translocation of the fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma SET domain (MMSET) on chromosome 4 with the IgH ge...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Henry Chan, Madeline Phillips, Manjula Maganti, Sophia Farooki, Giovanni Piza Rodriguez, Esther Masih-Khan, Christine Chen, Anca Prica, Donna Reece, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti Tags: Original Study Source Type: research

A Comparison of the Efficacy of Immunomodulatory-Containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis
A systematic review and network meta-analysis were conducted to compare the clinical efficacy of immunomodulatory drug –containing regimens in patients with RRMM. Daratumumab plus lenalidomide and dexamethasone had a significant advantage in improving progression-free survival in patients compared to other immunomodulatory-containing regimens. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 4, 2018 Category: Hematology Authors: Meletios Athanasios Dimopoulos, Jonathan L. Kaufman, Darrell White, Gordon Cook, Maria Rizzo, Yingxin Xu, Kyle Fahrbach, Maren Gaudig, Mary Slavcev, Lindsay Dearden, Annette Lam Tags: Original Study Source Type: research

SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma
Until recently, advances in classical Hodgkin lymphoma (HL) treatment primarily consisted of minor modifications of highly effective decades-old chemotherapy and radiation approaches. In early stage disease, excellent outcomes have been reported with fewer cycles of chemotherapy, lower doses and smaller radiation fields, and in some circumstances radiation elimination. In advanced stage disease, maintaining dose intensity of standard chemotherapy regimens has resulted in modest improvements in outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 4, 2018 Category: Hematology Authors: Marcus P. Watkins, Michelle A. Fanale, Nancy L. Bartlett Tags: Review Article Source Type: research

HIV-Related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab
We present a case of a patient with well-controlled human immunodeficiency virus (HIV) infection and refractory classical Hodgkin lymphoma (HL) treated with nivolumab as fifth-line treatment, who achieved complete response (CR) by positron emission tomography –computed tomography (PET/CT). To our knowledge, this is the second case report of a patient exhibiting nivolumab’s response, and first reported CR in the setting of HIV-associated HL (HIV-HL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 3, 2018 Category: Hematology Authors: Elaine Chang, Gustavo Rivero, Niraj R. Patel, Elizabeth Y. Chiao, Syeling Lai, Kelash Bajaj, John E. Mbue, Sarvari V. Yellapragada Tags: Case Report Source Type: research

Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom
A Markov model was used to assess the cost-effectiveness of ibrutinib compared with obinituzumab in combination with chlorambucil for untreated patients in the United Kingdom. The results showed ibrutinib not to be cost-effective. However, additional analyses showed ibrutinib to be significantly cost-effective compared with the current mode of care in which ibrutinib is administered as the second-line treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Richa Sinha, William Ken Redekop Tags: Original Study Source Type: research

Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging
The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved according to positron emission tomography-computed tomography imaging after chemotherapy. In this series, low-dose (approximately 20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Long-term toxicity was similar between chemotherapy and combined modality therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Erin J. Song, Jordan Torok, Yuan Wu, Junzo Chino, Leonard R. Prosnitz, Anne W. Beaven, Chris R. Kelsey Tags: Original Study Source Type: research

Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma in Complete Metabolic Response by PET-CT or Gallium
The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved by PET-CT after chemotherapy. In this series, low-dose ( ∼20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD. Long-term toxicity was similar between chemotherapy and combined modality therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Erin J. Song, Jordan Torok, Yuan Wu, Junzo Chino, Leonard R. Prosnitz, Anne W. Beaven, Chris R. Kelsey Tags: Original Study Source Type: research

Mechanisms of Hypercalcemia in non-Hodgkin Lymphoma and Associated Outcomes: a Retrospective Review
The etiology of hypercalcemia in non-Hodgkin lymphoma (NHL) is most often attributed to either elevated serum levels of 1,25-dihydroxycholecalciferol (calcitriol) or parathyroid-related protein (PTHrP). In a single center retrospective review we evaluated the incidence of and outcomes associated with hypercalcemia in NHL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Rory M. Shallis, Rachel S. Rome, John L. Reagan Tags: Original Study Source Type: research

Cost-effectiveness of ibrutinib compared to obinutuzumab plus chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom
A Markov model was used to assess the cost-effectiveness of ibrutinib compared to obinituzumab in combination with chlorambucil for untreated patients in the United Kingdom. The results demonstrated ibrutinib not to be cost-effective. However, additional analyses demonstrated ibrutinib to be significantly cost-effective when compared to the current mode of care in which ibrutinib is administered as the second-line treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Richa Sinha, William Ken Redekop Tags: Original Study Source Type: research

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
HRQoL was evaluated among RBC-TD patients with lower-risk non-del(5q) MDS treated with lenalidomide (n = 160) or placebo (n = 79) in the phase 3 MDS-005 study. Lenalidomide did not worsen HRQoL; response to lenalidomide was associated with significant HRQoL improvement. Lenalidomide represents a treatment option for patients with lower-risk non-del(5q) MDS who are ineligible for or refractory to ESAs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, Uwe Platzbecker, Rena Buckstein, C.L. Beach, Shien Guo, Arman Altincatal, Chengqing Wu, Pierre Fenaux Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 23, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 23, 2017 Category: Hematology Source Type: research

Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation
We have read with great interest the paper by Trifilio and colleagues,1 entitled “Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.” The authors illustrated the result of a retrospective comparative clinical trial of an olanzapine-cont aining regimen versus an aprepitant- or fosaprepitant-containing regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) among patients affected by multiple myeloma undergoing autologous stem cell transplantation (ASCT...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 22, 2017 Category: Hematology Authors: Andrea Tendas, Francesco Marchesi, Ombretta Annibali, Debora Saltarelli, Pasquale Niscola, Alessio Pio Perrotti, William Arcese, Rome Transplant Network Tags: Letter to the Editor Source Type: research